To date, multiple clinical trials have shown that monoclonal, bispecific, and drug-conjugated B7-H3 antibodies (MGA271 and 8H9) are safe and effective for the treatment of advanced malignant tumors [25–29]. The gene discussed is CD276; the disease is cancer.